Target diversity creates opportunity in chronic urticaria 

Dupixent’s April approval marked the first new targeted therapy for chronic urticaria in over a decade, while opening the door to a pipeline of agents pursuing mechanisms beyond IgE inhibition.

With at least seven therapeutic mechanisms in play, the urticaria pipeline shows companies see multiple avenues to improve on today’s options. Efforts focus on faster or more durable symptom relief, oral delivery, and treatments for patients who don’t respond to existing drugs...